Insider Buying: Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Purchases 21,802 Shares of Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGLGet Rating) Director Clay Thorp acquired 21,802 shares of the firm’s stock in a transaction on Monday, May 16th. The stock was bought at an average price of $2.76 per share, for a total transaction of $60,173.52. Following the completion of the acquisition, the director now owns 1,541,137 shares of the company’s stock, valued at $4,253,538.12. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Clay Thorp also recently made the following trade(s):

  • On Monday, March 28th, Clay Thorp acquired 3,000 shares of Vigil Neuroscience stock. The stock was bought at an average price of $7.20 per share, for a total transaction of $21,600.00.

Vigil Neuroscience stock opened at $3.16 on Wednesday. The business’s fifty day moving average is $6.54. Vigil Neuroscience, Inc. has a one year low of $2.18 and a one year high of $18.27.

Vigil Neuroscience (NASDAQ:VIGLGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). On average, equities analysts forecast that Vigil Neuroscience, Inc. will post -2.86 earnings per share for the current year.

Several equities analysts have commented on VIGL shares. Guggenheim started coverage on shares of Vigil Neuroscience in a report on Tuesday, February 1st. They issued a “buy” rating and a $23.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Vigil Neuroscience in a report on Tuesday, February 1st. They issued a “buy” rating and a $24.00 price objective on the stock. Morgan Stanley initiated coverage on shares of Vigil Neuroscience in a report on Tuesday, February 1st. They issued an “equal weight” rating and a $17.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Vigil Neuroscience in a research note on Tuesday, February 1st. They issued a “buy” rating and a $20.00 price target on the stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund acquired a new stake in shares of Vigil Neuroscience in the 1st quarter valued at $60,000. Point72 Hong Kong Ltd acquired a new stake in Vigil Neuroscience in the first quarter valued at about $89,000. Bank of New York Mellon Corp bought a new position in Vigil Neuroscience in the first quarter valued at about $94,000. Charles Schwab Investment Management Inc. acquired a new position in Vigil Neuroscience during the first quarter worth about $135,000. Finally, Renaissance Technologies LLC bought a new position in shares of Vigil Neuroscience in the first quarter worth about $141,000. Hedge funds and other institutional investors own 39.39% of the company’s stock.

Vigil Neuroscience Company Profile (Get Rating)

Vigil Neuroscience, Inc, a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease.

Featured Articles

Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.